Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cue Biopharma, Inc.

0.9600
-0.0092-0.95%
Post-market: 0.96000.00000.00%16:00 EDT
Volume:120.92K
Turnover:116.30K
Market Cap:60.82M
PE:-1.07
High:1.05
Open:1.01
Low:0.9200
Close:0.9692
1D
5D
D
W
M
Q
Y
1m
5m
10m
15m
30m
1h
2h
More
1D
5D
D
W
M
Q
Y
1m
5m
10m
15m
30m
1h
2h

Company Profile

Company Name:
Cue Biopharma, Inc.
Exchange:
NASDAQ
Establishment Date:
2014
Employees:
53
Office Location:
40 Guest Street,Boston,Massachusetts,United States
Zip Code:
02135
Fax:
- -
Introduction:
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Directors

Name
Position
Daniel R. Passeri
Chief Executive Officer, President and Director
Peter A. Kiener
Chairman and Director
Anthony DiGiandomencio
Director
Barry Simon
Director
Cameron Gray
Director
Christopher Marlett
Director
Steven McKnight
Director

Shareholders

Name
Position
Daniel R. Passeri
Chief Executive Officer, President and Director
Anish Suri
Senior Vice President and Chief Scientific Officer
Colin G. Sandercock
Senior Vice President, General Counsel and Secretary
Ken Pienta
Chief Medical Officer
Kerri Ann Millar
Vice President, Finance
Rodolfo Chaparro
Executive Vice President, Head of Immunology
Ronald Seidel, III
Executive Vice President, Head of Research and Development

If the download button clicks without skipping, click on the top right menu and select "Open in Browser."